Roche Group posts solid sales growth in first nine months
- Details
- Category: Roche
In the first nine months of 2010 Group sales rose 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs. Excluding Tamiflu sales, which as expected were significantly lower than in the previous year, Group sales increased 6% (3% in Swiss francs, 7% in US dollars).
GSK outlines approach to delivering advances in the treatment of rare diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) provided further details about the strategic focus and development priorities of the company's unit dedicated to rare diseases. Following the announcement of a new alliance with Fondazione Telethon and Fondazione San Raffaele, Marc Dunoyer, Global Head of GlaxoSmithKline Rare Diseases, outlined his ambitions for the unit and its potential to deliver significant benefits to underserved patient groups worldwide.
Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
- Details
- Category: Novartis
Novartis announced that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Aclasta* (zoledronic acid 5 mg) in postmenopausal women with osteoporosis[1]. The study of more than 1,200 women was presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
- Details
- Category: Bayer
New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with Betaferon® (interferon beta-1b) had a 39.3% relative reduced risk in mortality for the time since randomization in the study (P=0.027), compared with patients receiving placebo for up to the first five years of treatment.
GSK increases support for WHO strategy to improve children's health
- Details
- Category: GlaxoSmithKline
At the launch of the World Health Organization's (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH).
Merck KGaA to Introduce RebiDose, the Rebif Single Use Pre-filled Pen for Treatment of Multiple Sclerosis
- Details
- Category: Merck Group
Merck KGaA announced the upcoming introduction of the new device RebiDose, the Rebif single use pre-filled pen, for the self-administration of Rebif (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).
Results from a national survey of Alzheimer's Disease
- Details
- Category: Pfizer
Results announced from a national survey of Alzheimer's disease (AD) caregivers found that memory loss and confusion, which are cognitive symptoms, in addition to personal safety, are the greatest concerns related to the progression of their loved one's AD.
More Pharma News ...
- Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability
- Lundbeck and Genmab enter into a research collaboration
- Novartis affirms commitment to sustain efforts toward final elimination of leprosy
- Pfizer to Acquire King Pharmaceuticals, Inc.
- Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST®
- Afatinib (BIBW 2992) triples progression free survival in phase III study in lung cancer patients
- Denosumab Delays the Onset of Bone Complications Compared to Zometa